Identification of the c-myc oncogene product in normal and malignant B cells.
Antiserum to a synthetic peptide corresponding to the carboxyl-terminus of the human c-myc protein immunoprecipitated a 48,000-dalton protein from a number of normal and malignant human and mouse cells. The size of the protein is consistent with the potential coding region predicted from the c-myc nucleotide sequence, and is the same for malignant cells carrying either a rearranged or an unrearranged c-myc oncogene. Because c-myc transcripts are expressed at higher levels in malignant than in normal B cells, it appears that an increased level of the c-myc protein rather than a change in the gene product is the relevant factor in determining transformation.
D001402:B-Lymphocytes / Q000502:physiology*; D002051:Burkitt Lymphoma / Q000235:genetics*; D005786:Gene Expression Regulation; D006801:Humans; D009857:Oncogenes; D010446:Peptide Fragments / Q000276:immunology; D011506:Proteins / Q000276:immunology / Q000302:isolation & purification*; D014170:Transformation, Genetic
D010446:Peptide Fragments; D011506:Proteins